JPRN-UMIN000000847已完成2 期
Therapeutic exploratory study of KCB-1B for patients with tibial shaft fracture - Therapeutic exploratory study of KCB-1B
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Multi fragmentary fracture 2)Pathological fracture 3)Patients with other sites fracture affecting loading exercise 4)Osteoporosis 5)History or complication of malignancy 6)History of allergy to food or medicine which contain gelatine 7)History of allergy to protein preparation 8)History of anaphylactic shock or status asthmaticus 9)Received administration of other trial drugs within 24 weeks 10)Pregnant women, nursing mothers or possibly pregnant women 11)Complication of serious renal disorders,liver disorders,hematological disorders and circulatory system disorders
研究者
相似试验
已完成
3 期
Confirmatory Study of KCB01 in PCI-eligible patients with coronary stenotic lesions that are difficult to expand with conventional POBACoronary Heart DiseaseJPRN-jRCT2032220438akamura Masato70
进行中（未招募）
1 期
Treatment of patients with cutaneous T-Zell LymphomEUCTR2014-000924-11-DERuprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor25
进行中（未招募）
1 期
Study of SKB264 to treat participants with advanced non-small cell lung cancer alone or as a combination treatmentCTIS2023-507270-41-00Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.278
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphomaMedDRA version: 16.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-DEovartis Pharma Services AG66
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractorydiffuse large B-cell lymphoma, mantle cell lymphoma and follicularlymphomaDiffuse large B-cell lymphoma, Mantle cell lymphoma and FollicularlymphomaMedDRA version: 14.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-ESovartis Farmacéutica S.A.66